注射剂在美容外科中的作用:财务影响
该研究回顾性分析了2004年1月至2013年12月单一外科医生执业中仅因A型肉毒毒素或软组织填充剂注射就诊的新患者,量化其后续侵入性美容手术的转化率及非侵入性与侵入性操作的总收入。375例患者中59例(15.7%)后续接受美容手术,平均间隔19个月,10年总收入762,470美元。
要点
- 375例注射新患者中59例(15.7%)后续接受美容手术,平均间隔19个月。
- 注射与手术10年合计收入762,470美元,其中注射524,771美元、手术396,166美元。
- 最常见的后续手术为面部提升22例(18.5%)、上睑成形21例(17.6%)、内镜眉提升15例(12.6%)。
核心结论
- 非侵入性美容手术是整形外科执业的重要组成部分。
- 仅因非侵入性治疗就诊于单一整形外科医生的患者中,有可测量且显著数量的患者最终接受了传统侵入性美容手术。
研究设计与样本
- 回顾性病历审查,纳入2004年1月至2013年12月单一外科医生执业中所有接受A型肉毒毒素或软组织填充剂注射的男性和女性患者。
- 仅纳入新就诊且仅寻求A型肉毒毒素或填充剂的患者,审查其在该10年期间是否最终接受侵入性美容手术。
- 使用账单记录计算非侵入性和侵入性美容手术的总收入。
主要发现
- 2004年1月至2013年12月,375例患者进入资深外科医生执业并明确要求接受非侵入性美容治疗,其中女性369例、男性6例。
- 375例患者中59例(15.7%)在首次非侵入性美容治疗后平均19个月接受美容手术。
- 注射治疗后最常见的初始侵入性美容手术为面部提升22例(18.5%)、上睑成形21例(17.6%)、内镜眉提升15例(12.6%)。
- 非侵入性美容治疗与侵入性手术合计收入在10年期间为762,470美元,其中注射总收入524,771美元、手术总收入396,166美元。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The plastic surgeon competes with both core and noncore physicians and surgeons for traditional cosmetic procedures. In 2007, the American Society for Aesthetic Plastic Surgery (ASAPS) and the American Society of Plastic Surgeons (ASPS) joined efforts to form a Cosmetic Medicine Task Force to further analyze this trend. OBJECTIVES: Our objective is to document and quantify the patient capture and total collections generated in a single surgeon's practice exclusive from Botulinum Toxin A and filler injections over a 10-year period. We subsequently identified the effect and importance that fillers and Botulinum Toxin A have on an active cosmetic practice. METHODS: A retrospective chart review of all male and female patients who received Botulinum Toxin A or soft tissue filler injections (noninvasive aesthetic treatment) in a single surgeons practice from January 2004 to December 2013 was undertaken. Only those patients new to the practice and who were exclusively seeking out Botulinum Toxin A or fillers were included in the study. Chart review then identified which of these selected patients ultimately underwent invasive aesthetic surgery during this 10-year period. Noninvasive and invasive aesthetic surgery total collections were calculated using billing records. RESULTS: From January 2004 to December 2013, 375 patients entered the senior surgeon's practice specifically requesting and receiving noninvasive aesthetic treatments. Of these 375 patients, 59 patients (15.7%) subsequently underwent an aesthetic surgery procedure at an average of 19 months following initial noninvasive aesthetic treatment. Of these 375 patients, 369 were female and 6 were male. The most common initial invasive aesthetic procedure performed after injectable treatment included 22 facelifts (18.5%), 21 upper eyelid blepharoplasties (17.6%), and 15 endoscopic brow lifts (12.6%). Total collections from noninvasive aesthetic sessions and invasive surgery combined represented US$762,470 over this 10-year span. This represented US$524,771 and US$396,166 in total collections for injectables and surgery respectively. CONCLUSIONS: Noninvasive aesthetic surgery is a critical part of a plastic surgery practice. A measurable and significant number of patients who sought out a single plastic surgeon exclusively for noninvasive treatment ultimately underwent traditional invasive cosmetic surgical procedures.
引用
- Richards BG, Schleicher WF, D'Souza GF, et al. The Role of Injectables in Aesthetic Surgery: Financial Implications. Aesthet Surg J. 2017. PMID: 29025237. doi:10.1093/asj/sjx136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。